ANDRX-Reaffirm Outperform Recommendation-Gruntal Research Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ANDRX-Reaffirm Outperform Recommendation-Gruntal Research

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Silverman who wrote (9)	11/13/1996 7:02:00 PM
From: PAUL ROBERT ST. ONGE	of 23

Andrx is positioned to take advantage of major controlled release patent expirations including Procardia, Cardizem, Tental, Dilacor, Seledane, Oruvail, Verelan, Tazac to mention a few. I would presume that your likely to see Andrx next ANDA's continue to be with difficult to produce drug area, primarily focusing on higher end sale units. Cardizem sales alone for 1995, were near $760 million, Dilacor around $140 milllion. Not a bad combination alone, along with the existing pipeline, and expected ANDA's. The main focus is how much Andrx has accomplished in such a short time-frame. I believe it will become one of the most progressive drug delivery companies, that continues to produce results. I also believe it will expand into the international market in many areas, and add to the potential growth. Bare in mind that the research reports exclude this possibilty in revenue totals and projections. Conservatively speaking the potential revenue totals will most likely not reveal themselves until mid-year 97. I believe that total could double.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next